Christina M. Annunziata

Christina M. Annunziata

Oncology

8081 Innovation Park Dr
Level 6 - Potomac Clinic
Fairfax, VA 22031

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 109 publications

Transcriptomic analysis of a phase 1 trial for intraperitoneal monocytes plus IFNs in ovarian cancer reveals support and recruitment of cell-mediated immunity.

Transcriptomic analysis of a phase 1 trial for intraperitoneal monocytes plus IFNs in ovarian cancer reveals support and recruitment of cell-mediated immunity.

Journal: Journal for immunotherapy of cancer

Published: August 16, 2026

IL1β/IL1R1/IRAK4 Drives Inflammatory Ovarian Cancer Seeding at the inflamed sites and Is Reversed by an IRAK4 inhibitor UR241-2.

IL1β/IL1R1/IRAK4 Drives Inflammatory Ovarian Cancer Seeding at the inflamed sites and Is Reversed by an IRAK4 inhibitor UR241-2.

Journal: bioRxiv : the preprint server for biology

Published: May 18, 2026

Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer.

Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer.

Journal: Gynecologic oncology

Published: January 11, 2026

RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer.

RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer.

Journal: Cell reports

Published: November 21, 2025

The 15th Biennial Rivkin Center ovarian cancer research symposium.

The 15th Biennial Rivkin Center ovarian cancer research symposium.

Journal: Gynecologic oncology

Published: November 06, 2025

CA turns 75: Looking at the future but never forgetting the roots.

CA turns 75: Looking at the future but never forgetting the roots.

Journal: CA: a cancer journal for clinicians

Published: November 03, 2025

American Cancer Society's Report on the Status of Cancer Disparities in the United States, 2025.

American Cancer Society's Report on the Status of Cancer Disparities in the United States, 2025.

Journal: CA: a cancer journal for clinicians

Published: October 10, 2025

IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer.

IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer.

Journal: Frontiers in immunology

Published: June 23, 2025

Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.

Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.

Journal: Oncotarget

Published: March 12, 2025

Highlighting American Cancer Society-funded research in CA: A Cancer Journal for Clinicians.

Highlighting American Cancer Society-funded research in CA: A Cancer Journal for Clinicians.

Journal: CA: a cancer journal for clinicians

Published: January 09, 2025

Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer.

Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer.

Journal: The New England journal of medicine

Published: January 08, 2025

Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancer.

Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancer.

Journal: Cell death & disease

Published: March 22, 2024

Showing 1-12 of 109

Last Updated: 09/26/2026